Spruce Biosciences (SPRB) director reports zero beneficial ownership on Form 3

Rhea-AI Filing Summary

Spruce Biosciences, Inc. filed a Form 3 initial beneficial ownership report for a company director, stating that no securities were beneficially owned as of 12/11/2025.

The report is filed by one reporting person under Section 16(a) and includes a power of attorney authorizing Samir Gharib, as attorney-in-fact, to sign on the reporting person's behalf.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Walbert Keli

(Last) (First) (Middle)

C/O SPRUCE BIOSCIENCES, INC.

611 GATEWAY BOULEVARD, SUITE 740

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/11/2025

3. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Samir Gharib, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this Form 3 filing disclose for Spruce Biosciences (SPRB)?

The Form 3 shows that a director of Spruce Biosciences, Inc. reported no securities beneficially owned as of 12/11/2025.

What is the relationship of the reporting person to Spruce Biosciences (SPRB)?

The reporting person is identified as a director of Spruce Biosciences, Inc. in the filing.

How many reporting persons are included in this Spruce Biosciences (SPRB) Form 3?

The document indicates that the Form 3 is filed by one reporting person, not by a group.

What is the event date for this Spruce Biosciences (SPRB) ownership report?

The date of the event requiring the statement is listed as 12/11/2025.

Who signed the Spruce Biosciences (SPRB) Form 3?

The Form 3 is signed "/s/ Samir Gharib", identified as Attorney-in-Fact for the reporting person, under a power of attorney (Exhibit 24).

Does the Form 3 show any derivative securities for Spruce Biosciences (SPRB)?

The remarks section states "No securities are beneficially owned", and no derivative securities holdings are listed in the provided tables.